We are excited to announce the appointment of Rosa del Campo, PhD, MD to our Scientific Advisory Board.
As part of our strategic vision and further expansion, we are glad to work closely with clinicians on the therapeutics. With this goal, the appoint of Rosa del Campo is a great addition to our scientific advisory team.
Dr. Del Campo is a research microbiologist on the clinic at Hospital Ramón y Cajal, Madrid. Rosa obtained her MD at University of Zaragoza (1994) where she also obtained her PhD (1998). She currently holds several positions on the board of different clinical and research organizations like the Human Microbiota Group of the Spanish Society of Infectious Disease and Clinical Microbiology (SEIMC-GEMBIOTA), she is a professor at University Alfonso X el Sabio, and member of the board at Spanish Society of Microbiology (SEM) and SEIMC.
Rosa focused her research on intestinal microbiota and fecal material transplant (FMT) being one of the leaders in Europe and Spain. She has clinical practice on FMT for infectious disease and is developing research on multidrug resistance. Over her successful career she has led several international projects, has received numerous awards and published over one hundred scientific manuscripts. Rosa joined the Scientific Advisory Board of Microviable Therapeutics in 2021 to advance clinical evidence of microbiota-based biotherapeutic products.